Hao M - Search Results

1

HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.

Wang Y, Weng X, Wang L, Hao M, Li Y, Hou L, Liang Y, Wu T, Yao M, Lin G, Jiang Y, Fu G, Hou Z, Meng X, Lu J, Wang J. Wang Y, et al. Among authors: hao m. J Clin Invest. 2018 Dec 3;128(12):5235-5250. doi: 10.1172/JCI99974. Epub 2018 Oct 22. J Clin Invest. 2018. PMID: 30204129 Free PMC article.

2

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. Sun X, et al. Among authors: hao m. Cancer Metastasis Rev. 2010 Dec;29(4):709-22. doi: 10.1007/s10555-010-9256-x. Cancer Metastasis Rev. 2010. PMID: 20839032 Free PMC article. Review.

3

Role of chemokine receptor CXCR7 in bladder cancer progression.

Hao M, Zheng J, Hou K, Wang J, Chen X, Lu X, Bo J, Xu C, Shen K, Wang J. Hao M, et al. Biochem Pharmacol. 2012 Jul 15;84(2):204-14. doi: 10.1016/j.bcp.2012.04.007. Epub 2012 Apr 13. Biochem Pharmacol. 2012. PMID: 22525723

4

Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression.

Zheng J, Xiong D, Sun X, Wang J, Hao M, Ding T, Xiao G, Wang X, Mao Y, Fu Y, Shen K, Wang J. Zheng J, et al. Among authors: hao m. Cancer Microenviron. 2012 Dec;5(3):285-93. doi: 10.1007/s12307-012-0103-1. Epub 2012 Apr 13. Cancer Microenviron. 2012. PMID: 22528874 Free PMC article.

5

HIC1 modulates prostate cancer progression by epigenetic modification.

Zheng J, Wang J, Sun X, Hao M, Ding T, Xiong D, Wang X, Zhu Y, Xiao G, Cheng G, Zhao M, Zhang J, Wang J. Zheng J, et al. Among authors: hao m. Clin Cancer Res. 2013 Mar 15;19(6):1400-10. doi: 10.1158/1078-0432.CCR-12-2888. Epub 2013 Jan 22. Clin Cancer Res. 2013. PMID: 23340301

6

Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.

Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K. Chen X, et al. Among authors: hao m. Mol Cancer Res. 2013 Oct;11(10):1269-78. doi: 10.1158/1541-7786.MCR-13-0212. Epub 2013 Jun 27. Mol Cancer Res. 2013. PMID: 23814023

7

HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.

Cheng G, Sun X, Wang J, Xiao G, Wang X, Fan X, Zu L, Hao M, Qu Q, Mao Y, Xue Y, Wang J. Cheng G, et al. Among authors: hao m. Cancer Res. 2014 Feb 1;74(3):862-72. doi: 10.1158/0008-5472.CAN-13-2420. Epub 2013 Dec 2. Cancer Res. 2014. PMID: 24295734

8

IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.

Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J. Sun X, et al. Among authors: hao m. Oncogene. 2014 Jun 9. doi: 10.1038/onc.2014.158. Epub 2014 Jun 9. Oncogene. 2014. PMID: 24909173 Retracted.

9

Bmi-1 expression modulates non-small cell lung cancer progression.

Xiong D, Ye Y, Fu Y, Wang J, Kuang B, Wang H, Wang X, Zu L, Xiao G, Hao M, Wang J. Xiong D, et al. Among authors: hao m. Cancer Biol Ther. 2015;16(5):756-63. doi: 10.1080/15384047.2015.1026472. Epub 2015 Apr 16. Cancer Biol Ther. 2015. PMID: 25880371 Free PMC article.

10

CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.

Xiao G, Wang X, Wang J, Zu L, Cheng G, Hao M, Sun X, Xue Y, Lu J, Wang J. Xiao G, et al. Among authors: hao m. Oncotarget. 2015 Jun 10;6(16):14165-78. doi: 10.18632/oncotarget.3690. Oncotarget. 2015. PMID: 25909173 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,825 results

Search Page